Immunoprotective oral whole cell vaccine for enterotoxigenic Escherichia coli diarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2

Evans, David C.

doi:10.1016/0378-1097(88)90164-4

Cited by 12 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common adverse events were diarrhea, nausea, loss of appetite, intestinal cramping, intestinal gurgling, headaches, malaise, and fatigue (Table 1). These symptoms are similar to those reported for previous challenges with B7A (9,35,36) and H10407 (2,11,12,14,18,20,35,37,54). Symptoms were less frequently reported and less severe after B7A challenge than after H10407 challenge (Table 1), and they were milder in volunteers challenged with the lower dose of B7A than in volunteers challenged with the higher dose.…”

Section: Resultssupporting

confidence: 85%

“…Symptoms were less frequently reported and less severe after B7A challenge than after H10407 challenge (Table 1), and they were milder in volunteers challenged with the lower dose of B7A than in volunteers challenged with the higher dose. For the volunteers who had diarrhea, the mean time from challenge to the first diarrheal stool was significantly shorter for the B7A groups than for the H10407 groups (P ϭ 0.0001) ( Table 2) and was shorter than the times in previous studies (14,55,58). For these volunteers, the mean total stool weights were significantly higher for the H10407 groups than for the B7A groups for the same dose (10 9 cells) or any dose (P ϭ 0.0123).…”

Section: Resultsmentioning

confidence: 72%

“…The protective role of the host immune response to specific antigens, such as CF or toxins, or of specific components of the immune system, such as secretory immunoglobulin A (IgA) in the intestine, is not well defined. Previous studies showed that CF were protective when volunteers were challenged with homologous strains of ETEC after they were either passively immunized with immunoglobulin with specific activity against CF (18,54) or actively immunized or infected (9,12,14,34,36,37,55). Antitoxic protection based on an immune response to the heat-labile toxin was suggested based on field trials by Clemens et al (6), who used the B subunit of whole-cell cholera vaccine and induced cross-protection against severe diarrhea caused by ETEC LT in immunized volunteers.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Immune Response, Ciprofloxacin Activity, and Gender Differences after Human Experimental Challenge by Two Strains of Enterotoxigenic Escherichia coli

et al. 2007

View full text Add to dashboard Cite

In order to test vaccines against enterotoxigenic Escherichia coli (ETEC)-10 CFU B7A or either dose of H10407. B7A had a shorter incubation period than H10407 (P ‫؍‬ 0.001) and caused milder illness; the mean diarrheal output after H10407 challenge was nearly twice that after B7A challenge (P ‫؍‬ 0.01). Females had more abdominal complaints, and males had a higher incidence of fever. Ciprofloxacin generally diminished or stopped symptoms and shedding by the second day of antibiotic treatment, but four subjects shed for one to four additional days. The immune responses to colonization factors CS6 and colonization factor antigen I (CFA/I) and to heat-labile toxin ( Enterotoxigenic Escherichia coli (ETEC)-induced diarrhea is recognized frequently in individuals who travel in developing countries around the world (4,7,8,26,29,47) and is a major medical problem for military personnel deployed in these countries (26,44,45). Since strict personal hygiene and avoidance of local water and fresh and undercooked foods are recommendations with which travelers have difficulty complying, other means to reduce the ETEC attack rate must be considered. The use of short-term chemoprophylaxis and self-treatment for diarrhea are effective for travelers who are unwilling to accept even a short period of illness because of the serious impact it would have on their overall mission. However, the routine use of antimicrobial prophylaxis for the general traveler is not recommended because of the potential for associated adverse drug reactions and the potential to worsen the problem of antibiotic resistance of enteric bacteria (8,25,29,43,47). These factors make development of vaccines against ETEC a priority.

show abstract

Section: Resultssupporting

confidence: 85%

Section: Resultsmentioning

confidence: 72%

mentioning

confidence: 99%

See 1 more Smart Citation

Immune Response, Ciprofloxacin Activity, and Gender Differences after Human Experimental Challenge by Two Strains of Enterotoxigenic Escherichia coli

et al. 2007

View full text Add to dashboard Cite

show abstract

“…To date, the only ETEC vaccine that has shown statistically significant protection in vaccination-challenge studies is the oral, colicin E2 treated, whole-cell vaccine evaluated by Evans et al [30,31]. However, lack of additional clinical development of that vaccine precludes any assessment of the utility of the human challenge model to predict field efficacy.…”

Section: Model Utilitymentioning

confidence: 99%

A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)

Porter

Riddle

Tribble

et al. 2011

Vaccine

View full text Add to dashboard Cite

show abstract

“…Several well-characterized ETEC strains have been used in challenge studies. ETEC strain H10407 has been used most frequently, having been fed to more than 250 subjects, most often for preventive ETEC vaccine proof-of-concept studies (2,11,12,14,18). ETEC H10407 was originally isolated from an adult with severe diarrhea in Dhaka, Bangladesh.…”

mentioning

confidence: 99%

Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic Escherichia coli Vaccines

Harro

Chakraborty

Feller

et al. 2011

Clin. Vaccine Immunol.

View full text Add to dashboard Cite

Enterotoxigenic Escherichia coli (ETEC) is a leading bacterial cause of infectious diarrhea in infants and adults living in developing countries and accounts for approximately 30% of traveler's diarrhea in visitors to these regions (6, 21, 23-26, 28, 29, 35). ETEC strains vary in their pathogenicity as a result of differences in the expression of heat-labile toxin (LT), heatstable toxin (ST), and several colonization factors (CFAs) that are associated with attachment and colonization in the gut (23,31). For more than 40 years, human challenge models have been the mainstay for the clinical evaluation of ETEC pathogenesis and immunology (7,15) and for the assessment of the therapeutic and protective efficacy of antibiotics (2), probiotics (4), and candidate vaccines (18,19). The recent availability of new resources for ETEC vaccine development has renewed interest in ETEC challenge models. A model with a reliably high attack rate (AR) could provide a vehicle for the evaluation and screening of vaccine efficacy before expensive, longterm field trials are conducted in areas where ETEC is endemic or among at-risk travelers.

show abstract

Immunoprotective oral whole cell vaccine for enterotoxigenic Escherichia coli diarrhea prepared by in situ destruction of chromosomal and plasmid DNA with colicin E2

Cited by 12 publications

References 30 publications

Immune Response, Ciprofloxacin Activity, and Gender Differences after Human Experimental Challenge by Two Strains of Enterotoxigenic Escherichia coli

Immune Response, Ciprofloxacin Activity, and Gender Differences after Human Experimental Challenge by Two Strains of Enterotoxigenic Escherichia coli

A systematic review of experimental infections with enterotoxigenic Escherichia coli (ETEC)

Refinement of a Human Challenge Model for Evaluation of Enterotoxigenic Escherichia coli Vaccines

Contact Info

Product

Resources

About